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Ferroptosis, a newly identified form of regulated cell death, is characterized by
overwhelming iron-dependent accumulation of lethal lipid reactive oxygen species (ROS).
Preventing cellular iron overload by reducing iron uptake and increasing iron storage
may contribute to inhibit ferroptosis. Mitochondrial ferritin (FtMt) is an iron-storage
protein that is located in the mitochondria, which has a significant role in modulating
cellular iron metabolism. Recent studies showed that FtMt played inhibitory effects
on oxidative stress-dependent neuronal cell damage. However, the potential role of
FtMt in the progress of ferroptosis in neuronal cells has not been studied. To explore
this, we established ferroptosis models of cell and drosophila by erastin treatment.
We found that overexpression of FtMt in neuroblastoma SH-SY5Y cells significantly
inhibited erastin-induced ferroptosis, which very likely was achieved by regulation of
iron homeostasis. Upon erastin treatment, significant increases of cellular labile iron
pool (LIP) and cytosolic ROS were observed in wild-type SH-SY5Y cells, but not in the
FtMt-overexpressed cells. Consistent with that, the alterations of iron-related proteins
in FtMt-overexpressed cells were different from that of the control cells. We further
investigated the role of FtMt in erastin-induced ferroptosis in transgenic drosophila.
We found that the wild-type drosophilas fed an erastin-containing diet didn’t survive
more than 3 weeks. In contrast, the FtMt overexpressing drosophilas fed the same
diet were survival very well. These results indicated that FtMt played a protective role
in erastin-induced ferroptosis.
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INTRODUCTION
The small molecule erastin triggers a unique iron-dependent form of non-apoptotic cell death
in cancer cells and certain normal cells, which was recently identified as ferroptosis (Dixon
et al., 2012). Ferroptosis is morphologically, biochemically and genetically distinct from apoptosis,
necrosis and autophagy, as it is characterized by the overwhelming iron-dependent accumulation
of lethal lipid reactive oxygen species (ROS) (Dixon et al., 2012; Xie et al., 2016). In ferroptosis, the
Abbreviations: FtMt, Mitochondrial ferritin; LIP, cellular labile iron pool; ROS, reactive oxygen species; NADPH,
nicotinamide adenine dinucleotide phosphate; NOX, NADPH-dependent oxidase; IRP2, iron regulator protein 2; TfR1,
transferrin receptor 1; VDAC, voltage-dependent anion channels.
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generation of ROS involves nicotinamide adenine dinucleotide
phosphate (NADPH)-dependent oxidase (NOX) family of
superoxide-producing enzymes and lipid peroxidation.
Ferroptosis is associated morphologically with the presence
of shrunken, electron-dense mitochondria, thereby induced cell
death (Dixon et al., 2012).
Iron plays a significant role in the progress of ferroptosis.
Studies have shown that the ferroptosis process could be blocked
by iron chelators and enhanced by exogenous lysosomal form
of iron (Dixon et al., 2012; Eling et al., 2015). A study by Reed
et al. found that knockdown the expression of iron regulator
protein 2 (IRP2) significantly promoted erastin-induced killing
(Reed and Pellecchia, 2012). IRP2 is an RNA-binding protein that
controls the translation of a group of mRNAs involved in iron
homeostasis. IRP2 expression decreases iron uptake by reducing
transferrin receptor (TfR) expression and increases free iron
storage by inducing ferritin expression (Henderson and Kühn,
1995; Schneider and Leibold, 2000; Meyron-Holtz et al., 2004).
Thus, IRP2 plays a protective role in ferroptosis by preventing
cellular iron overload. Reducing iron uptake and/or increasing
iron storage may potentially inhibit ferroptosis.
Mitochondrial ferritin (FtMt) is an iron-storage protein
located in mitochondria, and has been characterized structurally
and functionally analogous to the well-characterized cytosolic
H-ferritin (Levi et al., 2001). The expression of FtMt is restricted
to mitochondria of cells of testes, the central nervous system,
and some other high oxygen-consumption tissues (Santambrogio
et al., 2007). FtMt has been shown to modulate cellular iron
metabolism dramatically (Corsi et al., 2002; Drysdale et al.,
2002; Cazzola et al., 2003). Previous studies suggested that
overexpression of FtMt caused redistribution of iron from
cytosol to mitochondria (Nie et al., 2005), thus high levels of
FtMt in mitochondria may prevent cytosolic iron accumulation.
Our previous studies have found that FtMt overexpression in
neuroblastoma SH-SY5Y cell increased its resistance to oxidative
stress (Shi et al., 2010; Wu et al., 2013), indicating FtMt
is not only involved in storing cellular iron, but may also
play a role in protecting mitochondria from iron-dependent
oxidative damage (Yang et al., 2013; Gao and Chang, 2014).
Our recent studies showed that FtMt overexpression protected
6-hydroxydopamine-indeced dopaminergic cell damage (You
et al., 2016), and FtMt played inhibitory effects on neuronal
tumor cell proliferation (Shi et al., 2015). Therefore, we speculate
that the FtMt might also play a very important protective role in
the new identified iron-dependent form of cell death, ferroptosis.
We used an FtMt-overexpressed neuroblastoma SH-SY5Y cell
line and induced ferroptosis by erastin treatment. In addition,
an in vivo transgenic drosophila melanogaster model was also
used. This study may provide inside into understanding the
functions of FtMt in ferroptosis and developing new strategies
for modulating ferroptosis-dependent cell death.
MATERIALS AND METHODS
Chemicals and Antibodies
DMEM medium, fetal calf serum and HEPES were
purchased from Gibco BRL (Grand Island, NY). Erastin,
2′,7′-dichlorofluorescein diacetate (DCF-DA), annexin V,
propidium iodide (PI), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium-bromide (MTT), Hoechst 33258,
calcein-AM, penicillin and streptomycin were purchased
from Sigma (St. Louis, MO). The salicylaldehyde isonicotinoyl
hydrazone (SIH) was synthesized as described previously (Shi
et al., 2010). The anti-mouse FtMt polyclonal antibody and
anti-human FtMt monoclonal antibody were gifts from Prof.
Sonia Levi. Anti-human β-actin polyclonal antibody (sc-130656,
1:3000 dilution), anti-human monoclonal L-ferritin antibody
(sc-390558, 1:1000 dilution), anti-human VDAC2 polyclonal
antibody (sc-32059, 1:1000 dilution) and anti-human NOX2
monoclonal antibody (sc-74514, 1:1000 dilution) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-human
VDAC3 antibody (14451-1-AP, 1:500 dilution) was purchased
from ProteinTech Group, Inc. (Chicago, IL). The anti-human
polyclonal TfR1 antibody (PA5-27739, 1:2000 dilution) was
purchased from Invitrogin (Shanghai, China).
Cell Lines and Erastin Treatment
The stable FtMt-expressing SH-SY5Y cell line (FtMt-SY5Y)
and pcDNA3.1(−) empty vector transfected cell line (vector-
SY5Y) were generated as described previously (Shi et al.,
2010). Briefly, the amplified mouse FtMt cDNA, with a
C-terminal hemagglutinin (HA) epitope sequence, was cloned
into pcDNA3.1(−) vector to generate construct of FtMt-
pcDNA3.1(−). The plasmids of FtMt-pcDNA3.1(−) and
empty vector were transfected into SH-SY5Y cells, and stable
transfectants were selected. The expression of mouse FtMt
protein was confirmed with western blotting by using anti-
HA antibody (Shi et al., 2010). The cells were maintained in
DMEM supplemented with heat-inactivated fetal calf serum
(10%, vol/vol), glucose (4.5mg/ml), penicillin (100U/ml) and
streptomycin (100µg/ml) in humidified 5% CO2 at 37
◦C.
Erastin was dissolved in DMSO. The stock solution of erastin
was prepared and stored at−20◦C in the dark.
Drosophila and Erastin Treatment
Three types of drosophila melanogasters wild-type (WT)W1118,
elav-Gal4 and UAS-Fer3HCH were gifts from Prof. Bing Zhou
at Tsinghua University. The USA-Fer3HCH flies overexpress
Fer3HCH (a mitochondrial ferritin subunit) under control of
the Gal4–upstream activating sequence (USA) system (Missirlis
et al., 2006). The elav-Gal4 is a pan-neuronal expressing driver
stain, which contributes to USA transgene expression in salivary
glands, neuroectodermal cells and embryonic nervous system
in early drosophila embryos (Tzortzopoulos and Skoulakis,
2007). To achieve overexpression of FtMt, we crossed the USA-
Fer3HCH flies to elav-Gal4 flies; while the crossing of USA-
Fer3HCH flies to W1118 (a strain not expressing Gal4) was
used as control. The flies were cultured at 25 ± 3◦C and 70–
80% relative humidity, and fed on a standard corn flour-agar
diet with yeast granules as the protein source. New hatching
drosophilas were subjected to CO2 narcosis, and female and
male drosophilas were separated under stereology microscope.
For erastin resistance test, 3-day-old male flies (both WT and
FtMt overexpressing strains) were chronically exposed to 10µM
Frontiers in Aging Neuroscience | www.frontiersin.org 2 December 2016 | Volume 8 | Article 308
Wang et al. FtMt Protects Erastin-Induced Ferroptosis
erastin in diet, and the medium were changed every 3 days to
avoid desiccation. Lethality of the flies was monitored until day
22. The Life span curves were obtained from independent trials
with a minimum of 100 flies per experiment. Experimental data
were presented as percentage of survival.
Cell Viability Assay
Cell viability was measured by MTT assay according to the
literature (Lu et al., 2009). In brief, the exponentially growing
SH-SY5Y cells, FtMt-SY5Y cells and vector-SY5Y cells were
seeded in a 96-well plate at a density of 1 × 104 cells/well.
After overnight incubation, the medium was replaced with
fresh medium with or without 10µM erastin, and cells were
incubated for the subsequent 24 h. Erastin-treated or untreated
cells were incubated in MTT (0.5mg/mL) for another 4 h, and
then cells were lysed with DMSO. The absorbance at 595 nm
was measured with a Bio-Rad model 3550 microplate reader
(Richmond, CA). The samples were measured in eight replicates,
and each experiment was repeated three times.
Measurement of Intracellular ROS
The level of intracellular ROS was quantified by measuring the
fluorescence of DCF-DA, according to Guo et al. (2005). After
treatment with or without 10µM erastin for 24 h, the cells
were collected and washed 3 times with 1×PBS, followed by
incubation with 5 µM DCF-DA for 45 min at 37◦C in the dark.
Cells were then washed 3 times with 1× PBS and resuspended in
a buffer containing 130mM NaCl, 5.4mM KCl, 0.8mM MgCl2,
1.8mM CaCl2, 15mM glucose and 5mM HEPES, pH 7.4. The
relative levels of fluorescence were quantified by fluorescence
spectrophotometer (Synergy H4; 488 nm excitation and 525 nm
emission).
Measurement of Mitochondrial ROS
All solutions and equipments for mitochondrial extraction were
pre-cooled and kept at 0–4◦C. Cells were centrifuged at 1000 g
for 15 min, resuspended in ice-cold 500µl of CHM buffer
(150mMMgCl2, 10mMKCl, 25mMTris-HCl, PH 6.7 and 1mM
EDTA), and kept on ice for 2 min. Cells were homogenized
with syringe by pipetting 20–30 times. 200µl of ice-cold CHM
containing 1M sucrose (final 0.25M) was added and gently
mixed with cells by repeated inversion. Nuclei were sediment by
centrifugation at 1000 g, 4◦C for 10 min, followed by another
centrifugation after removing the supernatant at 10000 g, 4◦C
for 10min. The pellet cell then washed with 1mL sucrose/Mg2+
medium and centrifuged at 10000 g, 4◦C for 10min. The obtained
mitochondria were resuspended with mt suspension medium I
(0.25M sucrose, 25 mM Tris-base, PH 7.0), and then plated in
96-well plates. The level of mitochondrial ROS was quantified
by measuring the fluorescence of DCF-DA (Guo et al., 2005).
The following procedures were same as the measurement of
intracellular ROS.
Measurement of Intracellular Labile Iron
Pool (LIP)
The LIP levels were measured according to the literature
(Epsztejn et al., 1997), with minor modifications. In brief, the
exponentially growing SH-SY5Y cells, vector-SY5Y, and FtMt-
SY5Y cells seeded in a 96-well plate at a density of 1 × 104
cells/well. After overnight incubation, the medium was replaced
with fresh medium with or without 10µM erastin, and cells were
incubated for another 24 h. After the cells were harvested, washed
and resuspended in a buffer containing 140mM NaCl, 5mM
KCl, 1mM MgCl2, 5.6mM glucose, 1.5mM CaCl2, and 20 mM
HEPES (pH 7.4). Calcein-AM was added at a final concentration
of 0.25 mM. The reaction mixture was incubated for 30 min at
37◦C, and then washed for 3 times. The cells were resuspended
in their respective well. The fluorescence intensity of calcein-
AM was quantified by Microplate reader (Synergy H4; 488 nm
excitation and 525 nm emission). After the baseline was stable,
SIH (final concentration of 100µM) was added. The reaction
mixture was subsequently incubated for 30 min at 37◦C, and the
fluorescence intensity was detected. The increase in fluorescence
intensity reflected the levels of calcein-bound iron.
Western Blotting
The method of western blotting has been described previously by
Shi et al. (2010). Briefly, cells were harvested, homogenized and
lysed with lysis buffer (50mM Tris–HCl, 150mM NaCl, 0.02%
NaN3, 100µg/ml PMSF, 1µg/ml aprotinin, 1µg/ml pepstatin A,
2µg/ml leupeptin and 1% Triton X-100). After centrifugation
at 12,000 g for 30 min at 4◦C, the supernatant was collected.
Protein concentration was determined by a BCA Protein Assay
kit (Pierce Biotechnology). ∼40µg of protein for each sample
was resolved by 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and then transferred to a
nitrocellulose membrane. The membrane was blocked by
incubating with 5% nonfat milk in PBS containing 0.1% Tween-
20 (PBS-T) for 1 h, and then hybridized with primary antibodies
overnight with constant agitation at 4◦C. After washing 3 times
for 15 min each with PBS-T, the membrane was incubated for
1 h with peroxidase-coupled secondary antibodies, and detected
with the ECL plus Western Blotting Detection Reagents (Pierce
Biotechnology, Rockford IL).
Statistical Analysis
All experiments were performed at least three times. One-way
ANOVAwas used to estimate the overall significance determined
by Tukey’s tests corrected for multiple comparisons. Data are
presented as mean ± SD. A probability level of 5% (p < 0.05)
was considered to be significant.
RESULTS
FtMt Expression Significantly Rescues
Erastin-Induced Neuronal Cell Death
The overexpression of mouse FtMt in SH-SY5Y cells was
confirmed by western blotting (Figure 1A). The endogenous
expression of human FtMt in SH-SY5Y cell line was very
low. To investigate the potential role of FtMt in erastin-
induced ferroptosis, we treated FtMt overexpressing cells (FtMt-
SY5Y), control SH-SY5Y and vector-SY5Y cells with erastin
(10µM) for 24 h. As shown in Figure 1B, remarkable decreases
in the viability of SH-SY5Y and vector-SY5Y cells were
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FIGURE 1 | Effects of FtMt on cell viability and survival rate of drosophilas treated with erastin. (A) The expressions of exogenous mouse FtMt (top panel)
and endogenous human FtMt (bottom panel) in FtMt overexpressed transfectants were examined by western blot using anti-mouse and anti-human FtMt antibodies,
respectively. K562-Mt6 is a human FtMt overexpressing cell line (a gift from Prof. Sonia Levi), which is used as a positive control. (B) The cell viability was measured
with the MTT assay. The wild-type (WT) SH-SY5Y cells, empty vector transfectants (vector), and FtMt overexpressed transfectants (FtMt) were treated with or without
10 µM erastin for 24 h. Data were presented as mean percentages of the cell viability compared with untreated WT control cells ± SD, n = 6 (*p < 0.05 and
**p < 0.01 vs. the untreated cells of same genotype; ##p < 0.01 vs. the erastin-treated vector control cells). (C) Modulatory effect of FtMt on erastin-induced
mortality. Survival rates of the WT W1118 drosophilas and FtMt overpressing flies, exposed to 10µM erastin containing or non-containing diet, were shown. Values
are means ± SD (n = 100 flies/replicate; three replications/group; from three different experiments).
observed. The viability of FtMt-SY5Y cells also decreased.
However, the decrease is significantly less than that of the
erastin-treated SH-SY5Y and vector-SY5Y cells, indicating that
FtMt overexpression rescued erastin-induced neuronal cell
death.
FtMt Overexpression Protected
Erastin-Induced Death in Drosophila
To obtain more comprehensive results, we studied the protective
role of FtMt overexpression on ferroptosis in vivo. Transgenic
FtMt overexpressing drosophilas were fed on a 10µM erastin
containing diet or non-containing diet, and their survival rates
were monitored over a period of time. The WT drosophila
under the same treatment condition was used as control. As
shown in Figure 1C, more than 50% of mortality was observed
in the WT drosophilas after 19 days of erastin treatment, and
no drosophila survived longer than 22 days. Interestingly, the
FtMt overexpressing drosophilas exposed to erastin-containing
diet survived very well. Only about 12.5% of drosophilas
died over the 22 days. These results implicated a protective
role that FtMt played against erastin-induced ferroptosis
in vivo.
FtMt Attenuates the Increase of VDAC2/3
and NOX2 in Erastin Treatment
The voltage-dependent anion channels (VDACs), particularly
VDAC2 and VDAC3, on mitochondrial membrane were found
as the essential targets of erastin (Yagoda et al., 2007), and
study by Dixon et al. had validated the upregulation of
VDAC2 and VDAC3 with erastin treatment (Dixon et al.,
2012). Therefore, we assessed the protein levels of VDAC2
and VDAC3 to further confirm the protective effect of FtMt
on erastin treatment. We found that both the levels of
VDAC2 and VDAC3 expression increased significantly in the
SH-SY5Y and vector-SY5Y cells following erastin treatment
(Figures 2A,B, respectively). However, the VDAC2 and VDAC3
levels didn’t alter significantly in FtMt-SY5Y cells with erastin
treatment as compared to the untreated FtMt-SY5Y cells,
suggesting a specific protective effect of FtMt on erastin-induced
ferroptosis.
Besides, we determined the activation of NADPH oxidase
2 (NOX2) in the three cell lines with or without erastin
treatment. It has been suggested that NADPH oxidase (NOX1
to 5) could be critical in the production of ROS in ferroptosis
(Dixon et al., 2012), and NOX2 appeared to be a major source
of pathological oxidative stress in the central nervous system
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FIGURE 2 | FtMt attenuated the increase of VDAC2/3 and inhibited NOX2 activation under erastin treatment. VDAC2 (A), VDAC3 (B) and NOX2 (C) levels
were determined by western blots. A representative blot image for each protein and its respective β-actin was shown. The expression levels in different groups were
calculated by normalizing the specific bands to their respective β-actin bands, and presented as means ± SD, n = 6 (**p < 0.01 vs. the untreated cells of same
genotype; ##p < 0.01 vs. the erastin-treated vector controls).
(Infanger et al., 2006; Sorce and Krause, 2009; Hur et al., 2010;
Nayernia et al., 2014). Studies have shown that the activation
of NOX2 enzyme remarkably promoted cell death in central
nervous system diseases (Sorce and Krause, 2009; Hur et al.,
2010; Nayernia et al., 2014; Marrali et al., 2016). Here, we
found that, after erastin treatment, the NOX2 indeed expressed
to a higher level after erastin treatment (Figure 2C), in both
WT SH-SY5Y and vector-transfected control cells. The increases
were statistically significant. Interestingly, the NOX2 level didn’t
increase much in the erastin-treated FtMt overexpressing cells
(Figure 2C). This inferred that the protective role of FtMt
in ferroptosis may attribute to its inhibitory effect on ROS
production.
FtMt Expression Attenuates
Erastin-Induced Accumulation of
Cytoplasmic ROS
Since erastin-induced ferroptosis has been shown to be
closely associated with cytoplasmic ROS production, and
the alterations of NOX2 were different among different
cells, we therefore measured the ROS production both in
cytoplasm and in mitochondria. As we predicted, erastin
treatment led to substantial increases in intracellular ROS
production in SH-SY5Y and vector-SY5Y cells (Figure 3A,
p < 0.01). However, only a slight increase was observed in FtMt-
overexpressed FtMt-SY5Y cells treated by erastin, which was
not statistically significant. These inferred that overexpression
of FtMt attenuated the erastin-induced accumulation of
intracellular ROS. We further isolated mitochondria and
detected mitochondrial ROS production. We found that the
mitochondrial ROS production had no obvious difference with
or without erastin treatment in all the three groups (Figure 3B).
These were consistent with the previous reported features of
ferroptosis.
Effects of FtMt on the LIP Level and Iron
Metabolism Under Erastin Treatment
The intracellular labile iron pool (LIP) of mammalian cells
has been suggested to be the cellular free-iron source that was
relatively accessible for Fenton reaction. Researchers have shown
that FtMt overexpression mobilized free iron and dramatically
redistributed cytosolic iron into mitochondria (Corsi et al.,
2002; Nie et al., 2005). The erastin-induced ferroptosis was also
closely dependent on the intracellular iron level. Therefore, we
determined the LIP level by using calcein-AM assay in the FtMt
-SY5Y cells and control cells under erastin treatment. As shown
in Figure 4A, LIP level in the control SH-SY5Y and vector-SY5Y
cells increased significantly after erastin treatment, attesting the
proposed damage effects of iron-dependent accumulation of ROS
in ferroptosis. In contrast, the FtMt-SY5Y cells only showed
a slight, insignificant increase in the LIP level after erastin
treatment.
We then detected the expression levels of iron-related
proteins, including iron-storage protein L-ferritin and iron-
uptake protein transferrin receptor 1 (TfR1). We found the
L-ferritin level dramatically upregulated in erastin-treated SH-
SY5Y and vector-SY5Y cells, reaching more than 8-times that
of the untreated control levels (Figure 4B). Again, the FtMt-
SY5Y cells didn’t show a large increase in the L-ferritin level
following erastin treatment. In erastin-treated SH-SY5Y and
vector-SY5Y cell, we also found the iron uptake protein TfR1
was significantly down-regulated (Figure 4C), suggesting the
existence of a cellular regulation of iron metabolism, possibly by
IRP, in response to the dramatically elevated intracellular iron
level.
DISCUSSION
Ferroptosis is closely associated with the level of intracellular
iron. The process of ferroptosis requires iron-dependent
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FIGURE 3 | FtMt expression attenuated erastin-induced accumulation of cytoplasmic ROS. (A) Cells treated with or without 10µM erastin were detected for
ROS production by DCF-DA fluorescence. (B) The mitochondrial ROS was detected by DCF-DA. The fluorescence level for each group was presented as
mean ± SD, n = 3 (**P < 0.01 vs. the untreated cells of same genotype; ##p < 0.01 vs. the erastin-treated vector controls).
FIGURE 4 | Effects of FtMt on the LIP level and iron metabolism under erastin treatment. (A) LIP levels were determined by the quenching of calcein-AM
fluorescence method using fluorescence spectrophotometer. The LIP level was presented as mean ± SD; n = 3 (**p < 0.01 vs. the untreated cells of same genotype;
##p < 0.01 vs. the erastin-treated vector controls). Ferritin (B) and TfR1 (C) levels were determined by western blots. A representative blot image for each protein and
its respective β-actin was shown. The expression levels in different groups were calculated by normalizing the specific bands to their respective β-actin bands, and
presented as means ± SD, n = 6 (**p < 0.01 vs. the untreated cells of same genotype; ##p < 0.01 vs. the erastin-treated vector controls).
production of ROS generated by Fenton-type reactions (Dixon
et al., 2012). Studies have shown that the ferroptosis process
could be blocked by iron chelators, while it was enhanced by
exogenous lysosomal form of iron (Dixon et al., 2012; Eling
et al., 2015). Mitochondrial ferritin (FtMt), an iron storage
protein located in mitochondria, was found in tissues with
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high levels of oxygen consumption (Santambrogio et al., 2007).
FtMt protected mitochondria from iron-dependent oxidative
damage by reducing cellular oxidative stress and ROS (Shi et al.,
2010; Wu et al., 2013). In this study, we found that the cell
viability markedly decreased in SH-SY5Y and vector-SY5Y cells
after erastin treatment, but not in the FtMt overexpressing
cells. This indicated that overexpression of FtMt protected
neuroblastma SH-SY5Y cells from erastin-induced ferroptosis.
In a transgenic drosophila model, the erastin-induced death in
drosophila was suppressed by the overexpressed FtMt, which
also indicated that FtMt indeed can suppress the erastin-induced
ferroptosis.
In erastin-induced ferroptosis, the VDAC2 and VDAC3,
present in the mitochondrial outer membrane, are the direct
targets of erastin (Yagoda et al., 2007), and RNAi interference
knockdown of VDAC2 may cause the resistance of erastin.
VDAC is a monomeric, voltage-gated channel that allows passage
of metabolites such as ATP, ADP, phosphocreatine and small
ions across the mitochondrial outer membrane (Colombini,
2007; Young et al., 2007). In addition to its role in energy
metabolism, VDAC has been tied to basic cellular processes
such as cytochrome-c dependent apoptosis (Shimizu et al., 1999;
Cheng et al., 2003). Our study found that FtMt can inhibit the
erastin-induced elevation in VDAC2 and VDAC3 expression,
which then resulted in the resistance of FtMt overexpressing cells
to erastin damage. However, the protective mechanisms of FtMt
on ferroptosis could be very complicated.
Similarly, the FtMt expression protected the cell from
ferroptosis by inhibiting erastin-induced elevation of NOX2
levels. As a major NADPH oxidase isoform in generation
of ROS, NOX2 activation remarkably promoted pathological
oxidative stress in the central nervous system (Sorce and Krause,
2009; Nayernia et al., 2014). Up-regulation of NOX2 has been
reported in the pathogenesis of Parkinson’s disease in human
patients and animal models (Glass et al., 2010), and NOX2
enzyme activation was also found in patients with chronic
inflammatory demyelinating polyneuropathy (Marrali et al.,
2016). Our findings indicated that NOX2-dependent oxidative
stress participated in the erastin-induced SH-SY5Y cell death,
whereas overexpression of FtMt suppressed the activation of
NOX2.
Subsequently, we determined the intracellular and
mitochondrial ROS levels in different cells with or without
erastin treatment. Results showed that the intracellular ROS
increased, but not the mitochondrial ROS, in the control
SH-SY5Y cells; whereas FtMt overexpression significantly
inhibited the erastin-induced increases in cytoplasmic ROS.
Since the primary function of FtMt is iron-storage, and it has
been shown to be involved in iron redistribution between
cytosol and mitochondria (Nie et al., 2005), intracellular
LIP level was detected in different cells. Consistent with
previous reports, the LIP levels were dramatically elevated
upon erastin treatment in control SH-SY5Y cells. However,
FtMt significantly inhibited LIP increase induced by erastin,
indicating that the antioxidative mechamism of FtMt against
erastin may predominately carry out through regulating
iron homeostasis. When iron levels elevated in the body, a
FIGURE 5 | A schematic representation of the proposed
neuroprotective mechanism of FtMt on erastin-induced neuronal
ferroptosis. Extracellular erastin treatment induced ferropotosis in
neuroblastoma SH-SY5Y cells, which involved the elevation of VDAC and NOX
levels and also depended on the increase of LIP level. The free iron may
donate electrons for the generation of ROS, and then cell is triggered to begin
the process of ferroptosis. The overexpressed FtMt may withdraw iron from
cytosol and inhibit ROS production. This in turn attenuated erastin-induced
ferrotptosis. The damaging effects caused by erastin treatment were indicated
with red arrows, while the protective effects of FtMt were indicated by green
arrows.
cellular iron regulatory pathway, the IRE/IRP system, would
be activated in order to attenuate the iron overload status. The
expression of iron-storage protein ferritin will be up-regulated
and iron-uptake protein TfR1 will be down-regulated. In our
study, increased L-ferritin level and decreased TfR1 expression
were observed in erastin-treated SH-SY5Y cells, whereas
the FtMt overexpression diminished these alterations. These
further attested the important role of FtMt in the modulation
of iron metabolism, and suggested that the neuroprotective
role of FtMt should be achieved through regulating iron
homeostasis.
In summary, our study suggested that FtMt played a
significant protective role in erastin-induced ferroptosis
(Figure 5). FtMt incorporated iron in mitochondria and directly
inhibited the erastin-induced LIP elevation and ROS production
in SH-SY5Y cells. The protection of FtMt on erroptosis was
also reflected by the suppression of VDAC2/3 expression and
NOX2 activation induced by erastin. This may link to its role
in regulating iron homeostasis although the exact mechanisms
from incorporating iron to altering the expressions of related
genes could be very complicated. Our study revealed the
protective effects of FtMt on erastin-induced ferroptotisis, which
may provide insight into identifying new targets for inhibiting
ferroptosis in neuronal cells.
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